Table 1.
Patient information. For each patient are indicated: age (gender), HLA (autologous), HLA of allogeneic donors (in bold overlapping HLA), number of cycles, efficacy of the treatment in terms of changes in tumor mass, if dead on week 40, toxicity observed (ERY, local erythema; HA, headache; NA, not applicable), overall survival (OS) from the relapse detection. UN, unavailable.
| Patient number | Age (gender) | HLA autologous | Known HLA allogeneic received | Cycles received | Efficacy | Dead | Toxicity observed | OS from relapse |
|---|---|---|---|---|---|---|---|---|
| 1 | 61 (F) | A 02/03 B 15/44 C 03/05 |
A 1/2/3/24/26/32/33 B 7/8/18/35/37/40/44/50/51 C 2/3/6/7 |
5 cycles 4 cycles |
Tumor regression Stable 17 wk Stable 28 wk |
Yes | ERY ERY + HA |
28 w >40 w |
| 2 | 65 (M) | A 11/26 B 44/52 C 14/12 |
A 1/2/3/24/32/33 B 7/8/15/18/35/37/40/44 C 2/3/4/5/6/7/12 |
4 cycles | Stable | ERY + HA | >40 w | |
| 3 | 47 (M) | UN | A 2/24/26/32/33 B 7/35/37/40/44/50/51 C 2/3/4/6/7 |
|||||
| 4 | 64 (F) | A 25/31 B 18/51 C 04/12 |
A 1/2/3/11/24/26 B 7/8/13/15/18/35/37/40/44/52 C 2/3/4/5/6/7/12/14 |
5 cycles | Stable 30 wk | ERY | >40 w | |
| 5 | 50 (F) | UN | A 1/2/3/11/24/26/30 B 8/13/15/18/35/44/52 C 3/4/5/6/7/12/14 |
3 cycles | Stable 26 wk Disease progression |
Yes | NA | 35 w |
| 6 | 52 (M) | UN | A 1/2/11/24 B 8/13/18/35/44 C 4/5/6/7 |
6 cycles | Tumor regression | NA | >40 w | |
| 7 | 57 (F) | A 03/68 B 27/35 C 04/07 |
A 1/2/3/11/24 B 8/13/15/18/35/44 C 3/4/5/6/7/ |
6 cycles | Stable | ERY | >40 w | |
| 8 | 28 (M) | A 02/24 B 07/49 C 07/– |
A 1/2/3/11/26/29/30/68 B 7/8/13/27/35/44/51/52 C 4/6/7/12/14/16 |
6 cycles | Stable | NA | >40 w | |
| 9 | 27 (F) | A 23/24 B 35/− C 04/− |
A 3/11/26/29/30/68 B 7/13/27/35/44/51/52 C 4/6/7/12/14/16 |
6 cycles | Stable | NA | >40 w |